Pneumococcal polysaccharide vaccines: Indications, efficacy and recommendations

  • G. A. W Bruyn
  • R. van Furth


Streptococcus pneumoniae is the primary cause of community-acquired pneumonia, meningitis in adults and otitis media in infants and children and the third cause of meningitis in infants and children. Despite the availability of effective therapeutic agents against this pathogen, mortality has remained high, particularly for infections complicated by bacteremia. For many years, there has been a plea for vaccination. The first steps, using whole bacterial vaccines, were taken during the early decades of this century in the gold mining camps of South Africa, where pneumonia was endemic. The efficacy of purified pneumococcal polysaccharide vaccines has since been demonstrated in young adults, such as gold miners and military recruits, as well as for several other groups at risk, such as institutionalized elderly, patients with sickle cell anemia or those who have undergone a splenectomy, and elderly patients with underlying conditions such as chronic obstructive pulmonary disease and chronic cardiovascular disease, but not in infants and severely immunocompromised patients. Serological studies on the immune response to inoculation of pneumococcal polysaccharide antigens have demonstrated a severely impaired antibody response in the last two groups. Therefore, development of more highly immunogenic vaccines, e.g. by linking pneumococcal polysaccharides or parts of them to protein carriers, should be continued in an attempt to offer adequate protection to those who are insufficiently protected by the current 23-valent polysaccharide vaccine. Opportunities to immunize other patients who are at risk for pneumococcal infection and are capable of responding to the current vaccine should not be missed.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Wright AE, Morgan PW, Colebrook L, Dodgson RW Observations on prophylactic inoculation againstpneumococcus infections, and on the results which have been achieved by it. Lancet 1914, i: 1–10, 87–95.Google Scholar
  2. 2.
    Ordnan D Pneumococcus types in South Africa. A study of their occurrence and distribution in the population and the effect thereon of prophylactic inoculation. Publications of the South African Institute of Medical Research 1938, 9: 1–28.Google Scholar
  3. 3.
    Francis T, Tillett WS Cutaneous reactions in pneumonia. The development of antibodies following the intradermal injection of type-specific polysaccharide. Journal of Experimental Medicine 1930, 52: 573–585.Google Scholar
  4. 4.
    Finland M, Sutliff WD Specific antibody response of human subjects to intracutaneous injection ofpneumococcus products. Journal of Experimental Medicine 1932, 55: 853–865.Google Scholar
  5. 5.
    Ekwurzel GM, Simmons JS, Dublin LI, Felton LD Studies on immunizing substances in pneumococci. VIII. Report on field tests to determine the prophylactic value ofpneumococcus antigen. Public Health Report 1938, 53: 1877–1893.Google Scholar
  6. 6.
    MacLeod CM, Hodges RG, Heidelberger M, Bernhard WG Prevention of pneumococcal pneumonia by immunization with specific capsular polysaccharides. Journal of Experimental Medicine 1945, 82: 445–465.Google Scholar
  7. 7.
    Kaufman P Pneumonia in old age. Active immunization against pneumonia withpneumococcus polysaccharide, results of a six year study. Archives of Internal Medicine 1947, 79: 518–531.Google Scholar
  8. 8.
    Heidelberger M, MacLeod CM, Kaiser SJ, Robinson B Antibody formation in volunteers following injection of pneumococci or their type-specific polysaccharides. Journal of Experimental Medicine 1946, 83: 303–320.Google Scholar
  9. 9.
    Heidelberger M, MacLeod CM, Hodges RG, Bernhard WG, Dilapi MM Antibody formation in men following injection of four type-specific polysaccharides ofpneumococcus. Journal of Experimental Medicine 1947, 85: 227–230.Google Scholar
  10. 10.
    Heidelberger M, MacLeod CM, Dilapi MM The human antibody response to simultaneous injection of six specific polysaccharides ofpneumococcus. Journal of Experimental Medicine 1949, 88: 369–372.Google Scholar
  11. 11.
    Heidelberger M, Dilapi MM, Siegel M, Walter AW Persistence of antibodies in human subjects injected with pneumococcal polysaccharides. Journal of Immunology 1950, 85: 535–541.Google Scholar
  12. 12.
    Austrian R, Gold J Pneumococcal bacteremia with special reference to bacteremic pneumococcal pneumonia. Annals of Internal Medicine 1964, 60: 759–776.PubMedGoogle Scholar
  13. 13.
    Bruyn GAW, van der Meer JWM, Hermans J, Knoppert W Pneumococcal bacteremia in adults over a 10-year period at University Hospital, Leiden. Reviews of Infectious Diseases 1988, 2: 446–450.Google Scholar
  14. 14.
    Austrian R, Douglas RM, Schiffman G, Coetzee AM, Koornhof HJ, Hayden-Smith SD, Reid RDW Prevention of pneumococcal pneumonia by vaccination. Transactions Association of American Physicians 1976, 89: 184–194.Google Scholar
  15. 15.
    Smit P, Oberholzer D, Hayden-Smith S, Koornhof HJ, Hilleman MR Protective efficacy of pneumococcal polysaccharide vaccines. Journal of the American Medical Association 1977, 238: 2613–2616.PubMedGoogle Scholar
  16. 16.
    Riley ID, Tarr PI, Andrews M, Pfeiffer M, Howard R, Challands P, Jennison G, Douglas RM Immunization with a polyvalent pneumococcal vaccine. Reduction of adult respiratory mortality in a New Guinea Highlands community. Lancet 1977, i: 1338–1341.Google Scholar
  17. 17.
    Hilleman MR, Carlson AJ, McLean AA, Weibel RE, Woodhour AF Streptococcus pneumoniae polysaccharide vaccine: age and dose responses, safety, persistence of antibody, revaccination, and simultaneous administration of pneumococcal and influenza vaccines. Reviews of Infectious Diseases 1981, 3, Supplement: 31–42.Google Scholar
  18. 18.
    Douglas RM, Paton JC, Duncan SJ, Hansmaan DJ Antibody response to pneumococcal vaccination in children younger than five years of age. Journal of Infectious Diseases 1983, 148: 131–137.PubMedGoogle Scholar
  19. 19.
    Borgono JM, McLean AA, Vella PP, Woodhour AF, Canepa I, Davidson WL, Hilleman MR Vaccination and revaccination with polyvalent pneumococcal polysaccharide vaccines in adults and infants. Proceedings of the Society for Experimental Biology and Medicine 1978, 157: 148–154.PubMedGoogle Scholar
  20. 20.
    Esposito AL Community-acquired bacteremic pneumococcal pneumonia. Archives of Internal Medicine 1984, 144: 945–948.PubMedGoogle Scholar
  21. 21.
    Bruyn GAW, Kremer HPH, Marie S, Padberg GW, Hermans J, van Furth R Clinical evaluation of pneumococcal meningitis in adults over a twelve-year period. European Journal of Clinical Microbiology and Infectious Diseases 1989, 8: 695–700.Google Scholar
  22. 22.
    Ruben FL, Uhrin M Specific immunoglobulin-class antibody responses in the elderly before and after 14-valent pneumococcal vaccine. Journal of Infectious Diseases 1985, 151: 845–848.PubMedGoogle Scholar
  23. 23.
    Austrian R Some observations on thepneumococcus and on the current status of pneumococcal disease and its prevention. Reviews of Infectious Diseases 1981, 3, Supplement: 1–17.Google Scholar
  24. 24.
    Bruyn GAW, Zegers BMJ, van Furth R: Mechanisms of host defense against infection withStreptococcus pneumoniae. Clinical Diseases 1992, 14.Google Scholar
  25. 25.
    Simberkoff MS, Cross AP, Al-Ibrahim M, Baltch AL, Geisler PJ, Nadler J, Richmond AS, Smith RP, Schiffman G, Shepard DS, Van Eeckhout JP Efficacy of pneumococcal vaccine in high-risk patients. Results of a Veterans Administration cooperative study. New England Journal of Medicine 1986, 315: 1318–1327.PubMedGoogle Scholar
  26. 26.
    Gaillat J, Zmirou D, Mallaret MR, Rouhan D, Stahl JP, Delormas P, Micoud M Essai clinique du vaccin antipneumococcique chez des personnes âgées vivant en institution. Revue d'Epidemiologie et de Sante Publique 1985, 33: 437–444.PubMedGoogle Scholar
  27. 27.
    Shapiro ED Pneumococcal vaccine failure. New England Journal of Medicine 1987, 316: 1272–1273.PubMedGoogle Scholar
  28. 28.
    Broome CV, Facklam RR, Fraser DW Pneumococcal disease after pneumococcal vaccination: an alternative method to estimate the efficacy of pneumococcal vaccine. New England Journal of Medicine 1980, 303: 549–552.PubMedGoogle Scholar
  29. 29.
    Bolan G, Broome CV, Facklam RR, Plikaytis BD, Fraser DW, Schlech WF Pneumococcal vaccine efficacy in selected populations in the United States. Annals of Internal Medicine 1986, 104: 1–6.PubMedGoogle Scholar
  30. 30.
    Shapiro ED, Clemens JD A controlled evaluation of the protective efficacy of pneumococcal vaccine for patients at high risk of serious pneumococcal infections. Annals of Internal Medicine 1984, 101: 325–330.PubMedGoogle Scholar
  31. 31.
    Forrester HL, Jahnigen DW, LaForce FM Inefficacy of pneumococcal vaccine in a high-risk population. American Journal of Medicine 1987, 83: 425–430.PubMedGoogle Scholar
  32. 32.
    Sims RV, Steinmann WC, McConville JH, King LR, Zwick WC, Schwartz JS The clinical effectiveness of pneumococcal vaccine in the elderly. Annals of Internal Medicine 1988, 108: 653–657.PubMedGoogle Scholar
  33. 33.
    Schwartz PE, Sterioff S, Mucha P, Melton LJ, Offord KP Postsplenectomy sepsis and mortality in adults. Journal of the American Medical Association 1982, 248: 2279–2283.PubMedGoogle Scholar
  34. 34.
    Hautekeete ML, Berneman ZN, Bieger R, Stevens WJ, Bridts A, Buyssens N, Peetermans ME Purpura fulminans in pneumococcal sepsis. Archives of Internal Medicine 1986, 146: 487–499.Google Scholar
  35. 35.
    Singer DB Postsplenectomy sepsis. In: Rosenberg HS, Bolande RP (ed): Perspectives in pediatric pathology, Volume I. Year Book Medical Publishers, Chicago 1973, p. 285–305.Google Scholar
  36. 36.
    Giebink GS, Foker JE, Kim Y, Schiffman G Serum antibody and opsonic responses to pneumococcal capsular polysaccharide vaccination in normal and splenectomized children. Journal of Infectious Diseases 1980, 141: 404–412.PubMedGoogle Scholar
  37. 37.
    Giebink GS, Le CT, Cosio FG, Spika JS, Schiffman G Serum antibody responses of high-risk children and adults to vaccination with capsular polysaccharides ofStreptococcus pneumoniae. Reviews of Infectious Diseases 1981, 3, Supplement: 168–178.Google Scholar
  38. 38.
    Sullivan JL, Ochs HD, Schiffman G, Hammerschlag MR, Miser J, Vichinsky E, Wedgwood RJ Immune response after splenectomy. Lancet 1978, i: 178–181.Google Scholar
  39. 39.
    Oldfield S, Jenkins S, Yeoman H, Gray D, MacLennan ICM Class and subclass anti-pneumococcal antibody responses in splenectomized patients. Clinical and Experimental Immunology 1985, 61: 664–673.PubMedGoogle Scholar
  40. 40.
    Aaberge IS, Michaelsen TE, Heier HE IgG subclass antibody responses to pneumococcal polysaccharide vaccine in splenectomized, otherwise normal, individuals. Scandinavian Journal of Immunology 1990, 31: 711–716.PubMedGoogle Scholar
  41. 41.
    Hosea SW, Burch CG, Brown EJ, Berg RA, Frank MM Impaired immune response of splenectomised patients to polyvalent pneumococcal vaccine. Lancet 1981, i: 804–807.Google Scholar
  42. 42.
    Nieuwhof WN, Hodgen AN An enzyme-linked immunosorbent assay suitable for the routine estimation of specific immunoglobulin G responses to polyvalent pneumococcal polysaccharide vaccine in humans. Journal of Immunological Methods 1985, 84: 197–202.PubMedGoogle Scholar
  43. 43.
    Robinson MG, Watson RJ Pneumococcal meningitis in sickle cell anemia. New England Journal of Medicine 1966, 274: 1006–1008.PubMedGoogle Scholar
  44. 44.
    Barrett DJ, Ammann AJ Pneumococcal vaccine in sickle cell disease: IgG and IgM antibody response. Reviews of Infectious Diseases 1981, 3, Supplement: 179–182.Google Scholar
  45. 45.
    Schwartz AD, Pearson HA Impaired antibody response to intravenous immunization in sickle cell anemia. Pediatric Research 1972, 6: 145–149.PubMedGoogle Scholar
  46. 46.
    Ammann AJ, Addiego J, Wara DW, Lubin B, Smith WB, Mentzer WC Polyvalent pneumococcal polysaccharide immunization of patients with sickle cell anemia and patients with splenectomy. New England Journal of Medicine 1977, 82: 897–900.Google Scholar
  47. 47.
    Gaston MH, Verter JI, Woods G, Pegelow C, Kelleher J, Presbury G, Zarkowsky H, Vichinsky E, Iyer R, Lobel JS, Diamond S, Holbrook T, Gill FM, Ritchey K, Falletta JM Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. New England Journal of Medicine 1986, 314: 1593–1599.PubMedGoogle Scholar
  48. 48.
    Chilcote RR, Baehner RL, Hammond D, Investigators and Special Committee of the Children's Cancer Study Group Septicemia and meningitis in children splenectomized for Hodgkin's disease. New England Journal of Medicine 1976, 295: 798–800.PubMedGoogle Scholar
  49. 49.
    Bruyn GAW Clinical and immunological aspects of pneumococcal infection. PhD Thesis, University of Leiden, Leiden, 1990, p. 117.Google Scholar
  50. 50.
    Siber GR, Wietzman SA, Aisenberg AC, Weinstein HJ, Schiffman G Impaired antibody response to pneumococcal vaccine after treatment for Hodgkin's disease. New England Journal of Medicine 1978, 299: 442–448.PubMedGoogle Scholar
  51. 51.
    Addiego JE, Ammann AJ, Schiffman G, Baehner R, Higgins G, Hammond D Response to pneumococcal polysaccharide vaccine in patients with untreated Hodgkin's disease. Lancet 1980, ii: 450–453.Google Scholar
  52. 52.
    Frederiksen B, Specht L, Henrichsen J, Pedersen FK, Pedersen-Bjergaard J Antibody response to pneumococcal vaccine in patients with early stage of Hodgkin's disease. European Journal of Haematology 1989, 43: 45–49.PubMedGoogle Scholar
  53. 53.
    Lindblad R, Kaijser B, Magnusson B, Rödjer S, Westin J Pneumococcal vaccination in splenectomized patients with hematological disorders. Acta Medica Scandinavia 1988, 224: 467–471.Google Scholar
  54. 54.
    Glenchur H, Zinneman HH, Hall WH A review of fifty-one cases of multiple mycloma: emphasis on pneumonia and other infections as complications. Archives of Internal Medicine 1959, 103: 173–183.Google Scholar
  55. 55.
    Bruyn GAW Idiotype and multiple mycloma. Masters' Thesis, Vrije Universiteit van Brussel, Brussels, 1982.Google Scholar
  56. 56.
    Lazarus HM, Lederman M, Lubin A, Herzig RH, Schiffman G, Jones P, Wine A, Rodman H Pneumococcal vaccination: the response of patients with multiple myeloma. American Journal of Medicine 1980, 69: 419–423.PubMedGoogle Scholar
  57. 57.
    Winston DJ, Schiffman G, Wang DC, Feig SA, Lin C-H, Marso EL, Ho WG, Young LS, Gale RP Pneumococcal infections after human bone-marrow transplantation. Annals of Internal Medicine 1979, 91: 835–841.PubMedGoogle Scholar
  58. 58.
    Sheridan JF, Tuschka PJ, Sedmak DD, Copelan EA Immunoglobulin G subclass deficiency and pneumococcal infection after allogeneic bone marrow transplantation. Blood 1990, 75: 1583–1586.PubMedGoogle Scholar
  59. 59.
    Winston DJ, Ho WG, Schiffman G, Champlin RE, Feig SA, Gale RP Pneumococcal vaccination of recipients of bone marrow transplants. Archives of Internal Medicine 1983, 143: 1735–1738.PubMedGoogle Scholar
  60. 60.
    Chave P, Bille J, Glauser MP, Francioli P Diagnosis of pulmonary infections in patients infected with the human immunodeficiency virus. European Journal of Clinical Microbiology and Infectious Diseases 1989, 8: 123–126.Google Scholar
  61. 61.
    Simberkoff MS, Sadr WE, Schiffman G, Rahal JJ Streptococcus pneumoniae infections and bacteremia in patients with acquired immune deficiency syndrome, with report of a pneumococcal vaccine failure. American Reviews of Respiratory Diseases 1984, 130: 1174–1176.Google Scholar
  62. 62.
    Stover DE, White DA, Romano PA, Gellene RA, Robeson WA Spectrum of pulmonary disease associated with the acquired immune deficiency syndrome. American Journal of Medicine 1985, 78: 429–437.PubMedGoogle Scholar
  63. 63.
    Klein RS, Selwyn PA, Maude D, Pollard C, Freeman K, Schiffman G Response to pneumococcal vaccine in asymptomatic heterosexual partners of persons with AIDS and intravenous drug users infected with human immunodeficiency virus. Journal of Infectious Diseases 1989, 160: 826–831.PubMedGoogle Scholar
  64. 64.
    Gilks CF, Brindle RJ, Otieno LS, Simani PM, Newnham RS, Bhatt SM, Lule GN, Okelo GBA, Watkins WM, Waiyaki PG, Were JBO, Warrell DA Life-threatening bacteraemia in HIV-1 seropositive adults admitted to hospital in Nairobi, Kenya. Lancet 1990, 336: 545–549.PubMedGoogle Scholar
  65. 65.
    Blumberg HM, Rimland D Nosocomial infection with penicillin-resistant pneumococci in patients with AIDS. Journal of Infectious Diseases 1989, 160: 725–726.PubMedGoogle Scholar
  66. 66.
    Ammann AJ, Schiffman G, Abrams D, Volberding P, Ziegler J, Conant M B-cell immunodeficiency in acquired immune deficiency syndrome. Journal of the American Medical Association 1984, 251: 1447–1449.PubMedGoogle Scholar
  67. 67.
    Huang K-L, Ruben FL, Rinaldo CR, Kingsley L, Lyter DW, Ho M Antibody responses after influenza and pneumococcal immunization in HIV-infected homosexual men. Journal of the American Medical Association 1987, 257: 2047–2050.PubMedGoogle Scholar
  68. 68.
    Ballet J-J, Sulcebe G, Couderc L-J, Danon F, Rabian C, Lathrop M, Clavel J-P, Seligmann M Impaired antipneumococcal antibody response in patients with AIDS-related persistent generalized lymphadenopathy. Clinical Experimental Immunology 1987, 68: 479–487.Google Scholar
  69. 69.
    Garin EH, Barrett DJ Pneumococcal polysaccharide immunization in patients with active nephrotic syndrome. Nephron 1988, 50: 383–388.PubMedGoogle Scholar
  70. 70.
    Simberkoff MS, Schiffman G, Katz LA, Spicehandler JR, Moldover NH, Rahal JJ Pneumococcal capsular polysaccharide vaccination in adult chronic hemodialysis patients. Journal of Laboratory and Clinical Medicine 1980, 96: 363–370.PubMedGoogle Scholar
  71. 71.
    Linneman C, First MR, Schiffman G Response to pneumococcal vaccine in hemodialysis and renal transplant patients. Archives of Internal Medicine 1981, 141: 1637–1640.PubMedGoogle Scholar
  72. 72.
    Van Dorp WT, Kootte AMM, Van Gemert GW Infections in renal transplant patients treated with cyclosporine or azathioprine. Scandinavian Journal of Infectious Diseases 1989, 21: 75–80.PubMedGoogle Scholar
  73. 73.
    Gransden WR, Eykyn SJ, Phillips I Pneumococcal bacteraemia: 325 episodes diagnosed at St Thomas's hospital. British Medical Journal 1985, 290: 505–509.PubMedGoogle Scholar
  74. 74.
    Mufson MA, Kruss DM, Wasil RE, Metzger WI Capsular types and outcome of bacteremic pneumococcal disease in the antibiotic era. Archives of Internal Medicine 1974, 134: 505–510.PubMedGoogle Scholar
  75. 75.
    Hook EW, Horton CA, Schaberg DR Failure of intensive care unit support to influence mortality from pneumococcal bacteremia. Journal of the American Medical Association 1983, 249: 1055–1057.PubMedGoogle Scholar
  76. 76.
    Williams JH, Moser KM Pneumococcal vaccine and patients with chronic lung disease. Annals of Internal Medicine 1986, 104: 106–109.PubMedGoogle Scholar
  77. 77.
    Davis AL, Aranda C, Christianson L, Schiffman G Pneumococcal antibodies in patients with chronic obstructive pulmonary disease and their response to pneumococcal polysaccharides: preliminary results. Reviews of Infectious Diseases 1981, 3, Supplement: 183–185.Google Scholar
  78. 78.
    Landesman SH, Smith PM, Schiffman G Pneumococcal vaccine in elderly patients with COPD. Chest 1983, 84: 433–435.PubMedGoogle Scholar
  79. 79.
    Musher DM, Chapman AJ, Goree A, Jonsson S, Briles D, Baughn RE Natural and vaccine-related immunity toStreptococcus pneumoniae. Journal of Infectious Diseases 1986, 154: 245–257.PubMedGoogle Scholar
  80. 80.
    Bruyn GAW, Hiemstra PS, Matze-van der Lans A, van Furth R Pneumococcal anticapsular antibodies in patients with chronic cardiovascular and obstructive lung disease in the Netherlands. Journal of Infectious Diseases 1990, 162: 1192–1194.PubMedGoogle Scholar
  81. 81.
    Lederman MM, Schiffman G, Rodman HM Pneumococcal immunization in adult diabetics. Diabetes 1981, 30: 119–121.PubMedGoogle Scholar
  82. 82.
    Beam TR, Crigler ED, Goldman JK, Schiffman G Antibody response to polyvalent pneumococcal polysaccharide vaccine in diabetics. Journal of the American Medical Association 1980, 244: 2621–2624.PubMedGoogle Scholar
  83. 83.
    Hellmann DB, Petri M, Whiting-O'Keefe Q Fatal infections in systemic lupus erythematosus: the role of opportunistic organisms. Medicine 1987, 66: 341–349.PubMedGoogle Scholar
  84. 84.
    Jonsson H, Nived O, Sturfelt G Outcome in systemic lupus erythematosus: a prospective study of patients from a defined population. Medicine 1989, 68: 141–150.PubMedGoogle Scholar
  85. 85.
    Klippel JH, Karsh J, Stahl NI, Decker JL, Steinberg AD, Schiffman G A controlled study of pneumococcal polysaccharide vaccine in systemic lupus erythematosus. Arthritis and Rheumatism 1979, 22: 1321–1325.PubMedGoogle Scholar
  86. 86.
    Karsh J, Pavlidis N, Schiffman G, Moutsopoulos HM Immunization of patients with Sjögren's syndrome with pneumococcal polysaccharide vaccine: a randomized trial. Arthritis and Rheumatism 1980, 23: 1294–1298.PubMedGoogle Scholar
  87. 87.
    Matter L, Wilhelm JA, Angehrn W, Skvaril F, Schopfer K Selective antibody deficiency and recurrent pneumococcal bacteremia in a patient with Sjögren's syndrome, hyperimmunoglobulinemia G, and deficiencies of IgG2 and IgG4. New England Journal of Medicine 1985, 312: 1039–1042.PubMedGoogle Scholar
  88. 88.
    Sell SH, Wright PF, Vaugh WK, Thompson J, Schiffman G Clinical studies of pneumococcal vaccines in infants. I. Reactogenicity and immunogenicity of two polyvalent polysaccharide vaccines. Reviews of Infectious Diseases 1981, 3, Supplement: 97–107.Google Scholar
  89. 89.
    Douglas RM, Miles HB Vaccination againstStreptococcus pneumoniae in childhood: lack of demonstrable benefit in Australian children. Journal of Infectious Diseases 1984, 149: 861–866.PubMedGoogle Scholar
  90. 90.
    Outbreak of invasive pneumococcal disease in a jail — Texas. Morbidity and Mortality Weekly Report. 1989. 1989, 38: 733–734.Google Scholar
  91. 91.
    Fattom A, Vann WF, Szu SC, Sutton A, Li X, Bryla D, Schiffman G, Robbins JB, Schneerson R Synthesis and physicochemical and immunological characterization of pneumococcus type 12F polysaccharidediphteria toxoid conjugates. Infection and Immunity 1988, 56: 2292–2298.PubMedGoogle Scholar
  92. 92.
    Anderson P, Betts R Human adult immunogenicity of protein-coupled pneumococcal capsular antigens of serotypes prevalent in otitis media. Pediatric Infectious Disease Journal 1989, 8: 50–53.Google Scholar
  93. 93.
    Schneerson R, Robbins JB, Parke JC, Bell C, Schlesselman JJ, Sutton A, Wang Z, Schiffman G, Karpas A, Shiloach J Quantitative and qualitative analyses of serum antibodies elicited in adults byHaemophilus influenzae type b andpneumococcus type 6A capsular polysaccharide-tetanus toxoid conjugates. Infection and Immunity 1986, 52: 519–528.PubMedGoogle Scholar
  94. 94.
    Peeters CCAM, Tenbergen-Meekes A, Evenberg DE, Poolman JT, Zegers BJM, Rijkers GT A comparative study of the immunogenicity of pneumococcal type 4 polysaccharide and oligosaccharide tetanus toxoid conjugates in adult mice. Journal of Immunology 1991, 146: 4308–4314.Google Scholar
  95. 95.
    Snippe H, Van Dam JEG, Van Houte AJ, Willers JMN, Kamerling JP, Vliegenthart JFG Preparation of a semisynthetic vaccine toStreptococcus pneumoniae type 3. Infection and Immunity 1983, 42: 842–844.PubMedGoogle Scholar
  96. 96.
    Van Dam JEG: Contribution to the development of a semi-synthetic vaccine toStreptococcus pneumoniae. PhD Thesis, Utrecht, 1988.Google Scholar
  97. 97.
    Zigterman GJWJ, Snippe H, Jansze M, Ernste E, De Reuver MJ, Willers JMN Nonionic block polymers as adjuvants for future vaccines. Advances Bioscience 1988, 68: 301–308.Google Scholar
  98. 98.
    Verheul AFM, Versteeg AA, De Reuver MJ, Jansze M, Snippe H Modulation of the immune response to pneumococcal type 14 capsular polysaccharide-protein conjugate by the adjuvant Quil A depends on the properties of the conjugates. Infection and Immunity 1989, 57: 1078–1083.PubMedGoogle Scholar

Copyright information

© Friedr. Vieweg & Sohn Verlagsgesellschaft mbH 1991

Authors and Affiliations

  • G. A. W Bruyn
    • 1
  • R. van Furth
    • 1
  1. 1.Department of Infectious DiseasesUniversity Hospital, LeidenLeidenThe Netherlands

Personalised recommendations